Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis
Author(s) -
F.–X. Blanc,
Sok Thim,
Didier Laureillard,
Laurence Borand,
Claire Rekacewicz,
Eric Nerrienet,
Yoann Madec,
Olivier Marcy,
Sarin Chan,
Narom Prak,
Chindamony Kim,
Khemarin Kim Lak,
Chanroeurn Hak,
Bunnet Dim,
Chhun Im Sin,
Sun Sath,
Bertrand Guillard,
Borann Sar,
Sirenda Vong,
Marcelo Fernandez,
Lawrence Fox,
JeanFrançois Delfraissy,
Anne E. Goldfeld
Publication year - 2011
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1013911
Subject(s) - medicine , tuberculosis , efavirenz , hazard ratio , lamivudine , stavudine , confidence interval , viral load , zidovudine , antiretroviral therapy , mortality rate , immunology , surgery , human immunodeficiency virus (hiv) , viral disease , virus , pathology , hepatitis b virus
Tuberculosis remains an important cause of death among patients infected with the human immunodeficiency virus (HIV). Robust data are lacking with regard to the timing for the initiation of antiretroviral therapy (ART) in relation to the start of antituberculosis therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom